| HOME >> BIOLOGY >> TECHNOLOGY |
ADDERALL XR 268.7 8% -5% 22.3%
VYVANSE 96.0 806% n/a 9.0%
DAYTRANA 18.1 93% -14% 1.6%
LIALDA / MEZAVANT 40.4 148% +143% 12.7%
PENTASA 49.2 13% 0% 16.6%
FOSRENOL 43.0 50% -1% 8.1%
XAGRID 19.4 15%
Human Genetic Therapies
ELAPRASE 78.2 42%
REPLAGAL 44.6 10%
FIRAZYR 0.2 n/a
(1) Product specific prescription data is provided by IMS Health
("IMS"), a leading global provider of business intelligence for the
pharmaceutical and healthcare industries. All other US market share data
stated in the text below is also provided by IMS.
(2) Compared to Q3 2007.
Specialty Pharmaceuticals
US ADHD market share
Shire's average quarterly market share of the US ADHD market rose to 32.9% in the three months to September 30, 2008 (2007: 29.7%), driven by the continued growth in market share of VYVANSE. The overall US ADHD market grew by 8% in the same period. Shire has the leading portfolio of products in the US ADHD market.
ADDERALL XR - ADHD
As a result of the launch of VYVANSE in July 2007, ADDERALL XR's average quarterly market share of the US ADHD market for Q3 2008 fell to 22.3% (2007: 25.2%), a decrease of 12% compared to the same period in 2007. US prescriptions for ADDERALL XR in the three months to September 30, 2008 decreased by 5% compared to the same period in 2007 due to the 12% decrease in the average market share offset by 8% growth in the US ADHD market.
Sales of ADDERALL XR for the three months to September 30, 2008 were
$268.7 million, an increase of 8% compared to the same period in 2007
(2007: $2
'/>"/>
| SOURCE Shire Plc Copyright©2008 PR Newswire. All rights reserved |